At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 199 enrolled
Drug / intervention
Donepezildrug
Likely dose
Donepezil 2.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
In Brief
A Phase 4 clinical trial evaluating Donepezil for Alzheimer's Disease. Completed, enrolled 199 participants across 15 sites.
Detailed Summary
This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedSep 2006
Primary CompletionAug 2008
Study CompletionDec 2008
TodayJul 2026
First PostedSep 27, 2006
Enrollment StartMay 31, 2006
Primary CompletionAug 31, 2008
Study CompletionDec 31, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.8 years ago
Interventions
Donepezildrug
2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.